20th Anniversary of Pharmaceuticals–Advances in Radiopharmaceutical Sciences and Nuclear Medicine

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 1252

Special Issue Editor

Department of Surgical Science, Uppsala University, 751 85 Uppsala, Sweden
Interests: nuclear medicine; radiochemistry; positron emission tomography; molecular imaging; radiopharmaceutical sciences; cancer; diabetes; fibrosis; drug development; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our great delight and honor to celebrate the 20th Anniversary of Pharmaceuticals with a Special Issue from the section of Radiopharmaceutical Sciences, and to invite the researchers to contribute a manuscript of original research, review, or short communication. The articles from this section of "Radiopharmaceutical Sciences" will be compiled into a dedicated book.

This Special Issue entitled “Advances in radiopharmaceutical sciences and nuclear medicine” aims to cover success stories of established radiopharmaceuticals, development of novel radiopharmaceuticals, latest advances in nuclear medicine, frontier developments, and visions for the future achievements.

The development of radiopharmaceuticals considers the design, synthesis and radiolabeling of the associated agents, their biological and preclinical evaluation, and finally clinical application. Contributions may concern targeted, pre-targeted, and non-targeted radiopharmaceuticals ranging from small molecules via peptides, peptidomimetics and antibodies and derivatives to particles for their use in gamma scintigraphy, including single photon emission tomography (SPECT), positron emission tomography (PET) and endo radiotherapy. The field of diagnostic imaging and (radio)pharmaceutical therapy guided by diagnostic imaging is of strong interest. Manuscripts on the related topics of physics, dosimetry, radiopharmacy, and hybrid imaging will also be accepted. Another area of interest is the implementation of computational chemistry for radiopharmaceutical development and machine learning for image analysis. Please refer to the keyword list below for additional details.

Dr. Irina Velikyan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiopharmaceuticals, agents and probes
  • radionuclides
  • imaging biomarkers
  • biological/preclinical evaluation
  • first in-human clinical studies
  • SPECT, PET/CT and PET/MRI
  • labeling chemistry
  • medicinal radiochemistry, (pre)clinical radiopharmacology, and radiopharmacy including GMP-compliant production
  • radiopharmaceutical drug development
  • radio theranostics
  • hybrid imaging
  • organic molecules, high-molecular weight biomolecules and nano- and microparticles
  • artificial intelligence and machine learning in image analysis
  • computational chemistry in radiopharmaceutical development

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 4342 KiB  
Article
Efficacy of Selective Internal Radiation Therapy for Hepatocellular Carcinoma Post-Incomplete Response to Chemoembolization
by Salma Binzaqr, Frederic Debordeaux, Jean-Frédéric Blanc, Panteleimon Papadopoulos, Elif Hindie, Bruno Lapouyade and Jean-Baptiste Pinaquy
Pharmaceuticals 2023, 16(12), 1676; https://doi.org/10.3390/ph16121676 - 01 Dec 2023
Cited by 1 | Viewed by 955
Abstract
Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide and the third most common cause of cancer-related death. Several liver-targeted intra-arterial therapies are available for unresectable HCC, including selective internal radiation therapy (SIRT) and trans-arterial chemoembolization (TACE). Those two are the [...] Read more.
Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide and the third most common cause of cancer-related death. Several liver-targeted intra-arterial therapies are available for unresectable HCC, including selective internal radiation therapy (SIRT) and trans-arterial chemoembolization (TACE). Those two are the most used treatment modalities in localized non-operable HCC. TACE is the treatment option for patients with stage B, according to the BCLC staging system. In contrast, SIRT does not have an official role in the treatment algorithm, but recent studies showed promising outcomes in patients treated with SIRT. Although TACE is globally a safe procedure, it might provoke several vascular complications such as spasms, inflammatory constriction, and, in severe cases, occlusion, dissection, or collateralization. Hence, it is acclaimed that those complications could restrain the targeted response of the radio-embolization when we use it as second-line therapy post TACE. In this study, we will assess the efficacity of SIRT using Yttrium 90 Microspheres post incomplete or failure response to TACE. In our retrospective study, we had 23 patients who met the inclusion criteria. Furthermore, those patients have been followed radiologically and biologically. Then, we evaluated the therapeutic effect according to the mRECIST criteria, in addition to the personalized dose analysis. We found 8 patients were treated with TheraSphere®, with a median tumor absorbed dose of 445 Gy, while 15 received SIR-Spheres® treatment with a mean tumor dose of 268 Gy. After radiological analysis, 56.5% of the patients had a complete response, and 17.3% showed partial response, whereas 13% had stable disease and 13% had progressive disease. For patients treated with SIRT after an incomplete response or failure to TACE, we found an objective response rate of 73.8%. Despite the known vascular complications of TACE, SIRT can give a favorable response. Full article
Show Figures

Figure 1

Back to TopTop